Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06946927 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation

StatusRecruiting
PhasePhase 1
SponsorJemincare
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 1, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 2025 to Jun 6, 2025
    • Site details revised
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase 1b, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and efficacy of JMKX001899 in combination with IN10018 or in combination with chemotherapy or in combination with IN10018 and chemotherapy in subjects with locally advanced or metastatic NSCLC with KRAS G12C mutation.
Trial Details
NCT Number NCT06946927
Lead Sponsor Jemincare
Conditions
(from sponsor)		 NSCLC (Advanced Non-small Cell Lung Cancer)
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 72 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov